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Background: Clinical and preclinical studies firmly support the involve-
ment of the inflammation in the pathogenesis of Alzheimer’s disease (AD).
Despite acetylcholinesterase inhibitors (AChEI) being widely used in
AD patients, there is no conclusive evidence about their impact on
the inflammatory response.
Methods: This study investigates peripheral proinflammatory cytokines
(interferon gamma [IFN-γ], tumor necrosis factor alpha [TNF-α], and in-
terleukins 1β [IL-1β] and 6 [IL-6]) by firstly comparing peripheral blood
mononuclear cell (PBMC)–derived secretion in drug-naïve and AChEI-
treated AD patients versus healthy controls. A subset of those drug-naïve
AD patients, who were prescribed the AChEI donepezil, was followed-up
for 6 months to investigate if donepezil suppresses proinflammatory cell-
derived cytokine secretion.
Results: Patients with AD showed higher levels of PBMC-derived proin-
flammatory cytokines (IFN-γ, TNF-α, IL-1β, and IL-6) in comparison with
healthy controls. On reexamination, previously drug-naïve AD patients
who received donepezil treatment for 6 months displayed a decrease in
cell-derived IFN-γ, TNF-α, IL-1β, and IL-6.
Conclusions: Proinflammatory PBMC-derived cytokineswere increased
in patients with AD in comparison with healthy controls and donepezil-
reduced proinflammatory cytokines when examining drug-naïve AD
patients before and after AChEI treatment.
Key Words: Alzheimer’s disease, inflammation, anticholinesterase
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A lzheimer's disease (AD), the most common type of dementia,is a progressive age-related neurodegenerative disorder clini-
cally characterized by a gradual and progressive impairment in
cognitive functions. Despite considerable progress in understand-
ing the pathophysiology of the disease,1,2 AD remains a complex,
multifactorial disorder with environmental, biological, and genetic
risk factors.3 Interestingly, there is increasing evidence about the
involvement of immune system abnormalities in AD pathology.4
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and highlight their pathogenic role, as intense expression of these
factors is found around Aβ deposition areas and neurofibrillary
tangles.5,6 Moreover, altered peripheral levels of interleukins 1β
(IL-1β), tumor necrosis factor alpha (TNF-α), and interleukin
(IL-6) are reported in patients with AD and higher blood serum
IL-1β levels associate with a more rapid cognitive decline.7,8
Although measurements in peripheral inflammatory markers may
only represent a partial reflection of brain pathology, peripheral
cytokine levels correlate well with brain inflammation and their
detection might be of use for disease assessment.9,10 Whereas ev-
idence firmly supports the involvement of inflammation in the path-
ogenesis of AD, there is still no conclusive evidence as to whether
acetylcholinesterase inhibitors (AChEI) can have an impact on the in-
flammatory response. The AChEI are consistently used in AD pa-
tients as symptomatic therapy, mostly helping with cognitive
and global outcome measures in a time-limited fashion.5 While
experimental data suggest an AChEI anti-inflammatory effect
on suppressing lymphocyte proliferation and proinflammatory
cytokine production,11–13 a recent clinical study failed to identify
any differences in IL1b, IL6, and TNFa after AChEI treatment.14
In this context, the present study investigated cell-derived proin-
flammatory cytokines by firstly comparing AChEI-treated and
drug-naïve AD patients with healthy controls. We then prospec-
tively followed-up a subset of those drug-naïve AD patients who
were prescribed the AChEI donepezil to investigate the hypothesis
that such treatment would suppress cell-derived proinflammatory
cytokine secretion.
METHODS
Patients
The present clinical sample is part of a larger effort on inves-
tigating genetic associations in AD, and further details of the pa-
tients’ characteristics have been reported previously.15–17 For
this study, 105 consecutive outpatients attending a psychogeriatric
outpatient service at the Department of Psychiatry in Medical
School of University of Athens were recruited. Informed consent
was obtained from all patients, and the study was approved by the
University of Athens Medical School Ethics Committee. Of them,
61 patients aged 75.9 (SD, 7.6) years with an average AD illness
duration of 2.5 (SD, 2.0) years were not receiving AChEIs at the
beginning of the study. Forty-four patients aged 73.9 (SD, 7.2)
years and with an average illness duration of 4.0 (2.4) years were
already under treatment with AChEIs. After informed consent, all
patients were examined with the Structured Clinical Interview for
the Diagnostic and Statistical Manual version IVAxis I Disorders
(SCID). Thereafter, patients underwent a screening evaluation
to determine if they met the following inclusion criteria: diag-
nosis of probable AD by National Institute of Neurological and018 www.psychopharmacology.com 1
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lated Disorders Association,18 Mini-Mental State Examination
(MMSE) score of ≥10, current residence at home, caregiver willing
to accompany the participant to study visits, stable medical his-
tory and general health. Patients with a lifetime diagnosis of
schizophrenia, bipolar disorder, or pre-AD anxiety disorder, cur-
rent substance use disorder, acutely suicidal, or requiring inpatient
psychiatric hospitalization were excluded from the study. Cogni-
tion was assessed using the MMSE, and the severity of dementia
was assessed with the Clinical Dementia Rating (CDR) scale.19
Depressive symptoms were measured by the Greek version of
the Cornell Scale for Depression in Dementia (CSDD).20 Addi-
tionally, 23 individuals aged 65.7 (SD, 6.9) years served as a con-
trol group. Those were randomly selected from the general
population in Athens, Greece, with the following criteria: older
than 60 years, MMSE score > 28, normal physical examination,
no history of neurological disease, and not meeting criteria for Di-
agnostic and Statistical Manual of Mental Disorders, version IV
axis I diagnosis according to the World Health Organization Com-
posite International Diagnostic Interview. For the follow-up study,
of the 61 patients not receiving an AChEI at baseline assessment,
22 patients (36%) were deemed suitable of being treated with
donepezil 10 mg/d. The treating physicians, who were blind to the
specific aims, measurements, and outcomes of this study, were re-
sponsible to decidewho of the original 61 patients would be treated
with donepezil, based on their best clinical judgment and routine
practices. There was no randomization to donepezil treatment and
no influence of this study to the standard care the patients would re-
ceive. Those 22 patients received a target dose of 10 mg daily, after
a 6-week titration schedule for reducing cholinergic adverse events
and were tested twice: at baseline, before treatment with donepezil,
and at 6 months after treatment with 10 mg/d of donepezil.Biological Sampling and Assays
Blood samples (20 mL) from all subjects were collected in
heparin-containing tubes and were immediately processed using
the Ficoll procedure. Briefly, 7 mL of peripheral blood collected
in heparin-containing tubes was layered on top of a 7 mL Ficoll–
Hypaque solution, according to manufacturers' instructions. After
centrifugation, erythrocytes and granulocytes sedimented at the
bottom of the tube and PBMCs (lymphocytes, monocytes) concen-
trated at the interface. By using aseptic techniques, the PBMCs
were collected in separate tubes, washed, counted, and resuspended
in 1.5 mL solution containing 80% fetal calf serum and 20% di-
methyl sulfoxide. Cell viability as measured by trypan blue exclusion
method always exceeded 95%. Peripheral bloodmononuclear cells
(1 106 cells/mL) containing Cryovials were stored in liquid nitro-
gen until analysis. For peripheral cytokines measurements, the
enzyme-linked immunospot (ELISPOT) method was performed,
which allows detection of real-time cytokine secretion by identify-
ing the number of cells that actively secrete cytokines at a given
time point with high sensitivity.21 Cytokines IL-1β, TNF-α, IL-6,
and IFN-γwere detected using a commercially available kit (Diaclone
Elispot, Diaclone SAS, France). Briefly, well plates bottomed
with polyvinylidene fluoride were coated with 25 μL/well of 70%
ethanol for 30 seconds at room temperature (RT) following and
washed 3 times with 100 μL (phosphate-buffered saline) PBS
per well. Then, 100 μL capturing antibody (100-μL antibody diluted
in 10 mL PBS) was dispensed into each well and was incubated
overnight at +4°C. Subsequently, wells were emptied, washed once
with 100-μL PBS, and incubated for 2 hours at RTwith a blocking
solution of 100 μL Roswell Park Memorial Institute medium sup-
plemented with 10% fetal calf serum. The plate was emptied and
washed once with PBS. Next, 100 μL of prepared cell suspension2 www.psychopharmacology.com
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the well-established mitogen PMA (phorbol 12-myristate 13-acetate,
200 ng/mL) was added for activation of T lymphocytes to secrete
cytokines and proliferate, as previously described.22 This cell
density provided the clearest ELISPOTenumeration without back-
ground and optimum, nontoxic cell activity was obtained with
200 ng/mL PMA (tested concentrations 150–450 ng/mL. The plate
was again emptied, wells filled with 100 μLPBS-T (PBSwith 0.1%
tween-20) for 10 minutes at +4°C and washed 3 times with PBS-T.
Subsequently, wells were filled with the detection antibody contain-
ing 1% bovine serum albumin and incubated for 90 minutes (RT).
After incubation, the plate was washed with PBS-T and was incu-
batedwith streptavidin–alkalinephosphatase solution (1:5000, 1hour,
RT). After washing, wells were incubated with 5-bromo-4-chloro-
3-indolyl-phosphate/nitro blue tetrazolium buffer for 45 minutes.
The reaction was stopped with distilled water, and the plate was
dried and automatically analyzed using Immunospot Analyzer.
Statistical Analysis
Data were tested for normality and equality of variance and
nonparametric testing was deemed more suitable and conserva-
tive. Comparisons between healthy subjects, AD patient without
treatment, and AD patients under treatment with AChEIs were
performed using the nonparametric Kruskal–Wallis (KW) test.
Post-hoc multiple comparisons were performed according to
Dunn's correction for type I error. Healthy subjects did not score
at the CSDD, and data were analyzed by comparing AD patients
with and without AChEI treatment using the 2-tailed nonparametric
Mann–Whitney U test, taking ties into account. All data before and
after treatment with AChEIs (donepezil) were tested using the
2-tailed non-parametric Wilcoxon/Pratt matched-pairs signed rank
exact test. Statistical analysis was performed using the Graphpad
Prism v.7.0b (GraphPad Software, La Jolla, CA). All values re-
ported are mean ± (SD). Statistical significance was set at P < 0.05.
RESULTS
Cross-Sectional Study: Comparison of Drug-Naïve
and AChEI-treated AD Patients With
Healthy Controls
As expected, healthy control subjects had higher MMSE scores
thandrug-naïveandunderAChEI treatmentADpatients (KW=53.12;
P < 0.0001; post hoc, P < 0.0001, P < 0.0001, respectively) (Table 1).
However, no difference was detected in the MMSE and CSDDmean
scores betweenADdrug-naïve patients and those receiving anAChEI
treatment. Interestingly, the CSDD median score of drug-naïve
AD patients was on average 4 points higher than those already
on an AChEI treatment (U = 591, P = 0.0028, 95% confidence
interval [CI] +0, +8 points) (Table 1).
Regarding IFN-γ, there were significant differences among
the 3 groups, either without or with PMA activation (KW = 56.19,
P < 0.0001; KW = 31.88, P < 0.0001; respectively). Healthy
controls had lower counts of PBMC cells secreting IFN-γ in
comparison with drug-naïve AD patients with and without
PMA activation (P < 0.0001 and P < 0.0001, respectively) and in
comparison with AChEI-treated AD patients (P < 0.0148 without
PMA activation, P < 0.0001 with PMA activation) (Fig. 1, A and B).
Tumor necrosis factor alpha was also significantly differenti-
ated among the 3 groups, either without or with PMA activation
(KW= 56.06, P < 0.0001; KW= 45.35, P < 0.0001; respectively).
Healthy controls had lower levels of PBMC cells secreting TNF-α,
either without or with PMA activation than AChEI-treated and
drug-naïve AD patients (P < 0.0001 for all 4 post-hoc comparisons)
(Fig. 1, C and D).© 2018 Wolters Kluwer Health, Inc. All rights reserved.
horized reproduction of this article is prohibited.
TABLE 1. Patient Characteristics, Demographics and Cell-Derived Cytokines for the Cross-sectional Part of the Study and the
Follow-Up of Drug-Naïve Patients After 6 Months of Donepezil Treatment
Cross-Sectional Study Drug-Naïve AD Followed-Up
Healthy Controls AChEI-Treated AD Drug-Naïve AD Baseline End Point
n 23 44 61 22 (36% of drug-naïve AD)
Females 43% 45% 64% 77%
Age 65.74 ± 6.99 73.98 ± 7.24 75.87 ± 7.59 75.73 ± 4.94
Illness duration N/A 4.02 ± 2.41 2.49 ± 2.05 1.93 ± 1.38
AchEI mean dose N/A 6.59 ± 2.53 0 0 10 mg/day
MMSE 28.83 ± 1.23 16.07 ± 5.19 18.43 ± 7.67 21.86 ± 5.16 19.05 ± 3.84
CSDD N/A 6.43 ± 7.13 7.28 ± 5.95 6.70 ± 5.28 3.47 ± 3.98
CDR early N/A 10% 44% 55% 41%
CDR mild N/A 45% 26% 27% 41%
CDR moderate N/A 38% 20% 14% 9%
CDR severe N/A 7% 10% 4% 9%
IFN-γ 210 ± 81 692 ± 264* 1099 ± 196* 1087 ± 230 968 ± 243†
IFN-γ PMA 713 ± 283 1068 ± 378* 1386 ± 461* 1388 ± 591 1192 ± 324
TNF-α 286 ± 124 930 ± 232* 1045 ± 278* 1146 ± 258 941 ± 222†
TNF-α PMA 720 ± 201 1272 ± 367* 1489 ± 605* 1733 ± 768 1246 ± 268†
IL-1β 253 ± 105 760 ± 565* 737 ± 390* 946 ± 257 1007 ± 197†
IL-1β PMA 548 ± 150 935 ± 755* 908 ± 543 1041 ± 288 753 ± 274†
IL-6 301 ± 99 940 ± 476* 1070 ± 323* 977 ± 357 772 ± 194
IL-6 PMA 781 ± 343 1125 ± 531* 1393 ± 564* 1254 ± 556 887 ± 180†
All values are reported as means ± SD.
*Denotes a significant difference of drug-naïve or AChEI-treated AD patients vs health controls.
†Indicates a significant difference of AD patients after 6 months of AChEI treatment vs before treatment.
Journal of Clinical Psychopharmacology • Volume 38, Number 2, April 2018 Donepezil & CytokinesSimilar differences were seen for IL-1β, either without or
with PMA activation (KW = 23.89, P < 0.0001; KW = 7.054,
P < 0.0294; respectively). Healthy controls had lower counts of
PBMC cells secreting IL-1β without or with PMA activation
in comparison with drug-naïve AD patients (P < 0.0001 and
P = 0.0246, respectively) and in comparison with AChEI-
treated AD patients without PMA activation only (P = 0.0006)
(Fig. 1, E and F).
Regarding IL-6, differences were detected among the 3 groups,
either without or with PMA activation (KW = 37.93, P < 0.0001;
KW = 16.69, P < 0.0001; respectively). Healthy controls had
fewer IL-6 secreting PBMC cells without or with PMA activation
than untreated AD patients (P < 0.0001 and P < 0.0001, respec-
tively), and fewer than AChEI-treated AD patients (P < 0.0001
and P = 0.0299, respectively) (Fig. 1, G and H).
Finally, drug-naïve and AD patients receiving an AChEI did
not differ in TNF-α, IL-1β, and IL-6. However, AChEI-treated
AD patients had lower IFN-γ PBMC counts than drug-naïve
AD patients (P = 0.0027) (Fig. 1A), but this difference was not
observed after PMA stimulation (Fig. 1B).Follow-Up Study: Effect of an AChEI (Donepezil)
Treatment on Drug-Naïve AD Patients
Of the 61 drug-naïve AD patients presented, 22 patients
(36%) were deemed suitable by the treating physicians of being
treated with donepezil 10 mg/d and they were tested twice:
at baseline, before treatment with donepezil, and at follow-up,
6 months after treatment with 10 mg/d of donepezil.
Patients reexamined after a 6-month treatment with donepezil
showed a significant reduction in the CSDD as indicated by the
Wilcoxon matched-pairs 2-tailed signed rank test (P = 0.001), with© 2018 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2018 Wolters Kluwer Health, Inc. Unaua median difference of 4 points (95% CI, −6 to 0 points). The CDR
score after 6 months did not show any significant deterioration, as
indicated by nonparametric testing, although a slight deterioration
was observed in the MMSE score after 6 months (Table 1).
The analysis showed a reduction in the number of PBMC
IFN-γ secreting cells at baseline (P = 0.0244) (Fig. 2A) but not
after PMA activation (Fig. 2B). Peripheral blood mononuclear
cells secreting TNF-α were also reduced after donepezil treatment
both before and after PMA (P = 0.0101 and P = 0.0239,
respectively) (Fig. 2, C and D). Interleukins 1β secreting cells
were significantly reduced by donepezil treatment, as measured
without and with PMA activation (P = 0.0009 and P = 0.0203,
respectively) (Fig. 2, E and F). Finally, a reduction of cells secreting
IL-6 was not evident without PMA stimulation (Fig. 2G), but
after stimulation, the reduction in PBMCs secreting IL-6 levels
was significant (P = 0.0268) (Fig. 2H).DISCUSSION
The current clinical study, based on patients with mainly
early/mild AD, demonstrates higher secretion of all monitored
proinflammatory cytokines among AD patients. This is in line
with previous evidence supporting the detrimental role of inflam-
matory cascades23 and demonstrating increased peripheral levels
of proinflammatory cytokines such as TNF-α, IL-1β, and IL-6,
as well as decreases in anti-inflammatory cytokines, such as
IL-4 in patients with AD.7,24,25 In contrast, negative results have
also been reported in other human studies.26 A recent meta-
analysis emphasized the variability of the peripheral cytokines in
patients with AD,27 highlighting the difficulty of defining a direct
link between peripheral (pro- and anti-) inflammatory cytokines
and the etiology or response to treatment in such a multifactorialwww.psychopharmacology.com 3
thorized reproduction of this article is prohibited.
FIGURE 1. Number of cells in 105 of PBMC secreting IFN-γ, TNF-α, IL-1β, and IL-6. Data on the left side represent basal secretion and, on
the right side, after Phorbol-12-Myristate-13-Acetate (PMA) stimulation. Two, 3, or 4 asterisks denote levels of significance (P < 0.01,
P < 0.001, and P < 0.0001, respectively) after nonparametric testing and post-hoc pairwise comparisons vs healthy controls. A pairwise
comparison between treated and untreated AD patients is noted with a horizontal line.
Kokras et al Journal of Clinical Psychopharmacology • Volume 38, Number 2, April 2018diseasewhere inflammatory cascades could be differently affected
in early (presymptomatic) and late (postsymptomatic) stages of
AD. In contrast to monitoring of the aforementioned cytokines,
very few studies have estimated systemic IFN-γ in AD patients9,28,29
and their possible involvement in the neurodegenerative process in
the brain. In previous studies, based on ELISA assays, IFN-γ levels
under basal conditions were either nondetectable28 or did not differ
among groups of AD patients and healthy controls.29 However, a pre-
vious study showed that PBMC of patients with moderate/severe, but
not early/mild, AD exhibit higher secretion of IFN-γwhen compared
with healthy controls.9 In our study, we demonstrate a clear difference
in IFN-γ between patients with early/mild AD and healthy controls.
The discrepancy between the current and previous studies could
be attributed to the selected method of cytokines estimation, as
ELISPOT might be more precise and accurate than ELISA in
the detection of released cytokines.
On the other hand, there are conflicting reports on patients
with AD regarding the effect of AChEIs on proinflammatory4 www.psychopharmacology.com
Copyright © 2018 Wolters Kluwer Health, Inc. Unautcytokines. Richardson et al14 found no AChEI-driven differences
in IL-1β, IL-6, and TNF-α. On the contrary, the current study
and previous studies showed that AChEI treatment reduced
levels of PBMC-derived proinflammatory cytokines IL-1,
IL-6, and TNF.24,30,31 A possible explanation for the above con-
flicting results among different clinical studies could be based
on the different length of AChEI treatment as AChEIs apparently
exert their action in a time-specific manner. In fact, while investi-
gating the profile of the short-term and long-term use of AChEIs,
a previous study detected a short-term AChEI effect on oxidative
stress markers, which was not found at long-term treatment.32
Indeed, the current study shows that, while secretion of proin-
flammatory cytokines (including IFN-γ) was significantly
higher in AD patients than healthy controls, 6-month donepezil
treatment in patients with early/mild stage of AD results in a
clear anti-inflammatory effect. However, despite this reduction,
cytokines of donepezil-treated AD patients remained higher in
comparison with healthy controls. A possible explanation is that© 2018 Wolters Kluwer Health, Inc. All rights reserved.
horized reproduction of this article is prohibited.
FIGURE 2. Effect of donepezil treatment on number of cells in 105 of PBMCs secreting IFN-γ, TNF-α, IL-1β, and IL-6. Baseline is before
commencing treatment, and the end point is after 6 months of donepezil treatment. One, 3, or 4 asterisks denote levels of significance
(P < 0.05, P < 0.001, and P < 0.0001, respectively) calculated by Wilcoxon/Pratt nonparametric test. The left column represents basal
secretion, and the right column contains data after PMA stimulation. On each pane, we report on the left values before (baseline) vs after
treatment (end point) and the horizontal line represents the group mean at baseline and at the end point (6 months). On the right side of each
pane, we depict the difference in absolute values for each patient to provide a better estimation of the effect of donepezil treatment on each
patient. A horizontal line depicts the mean difference, and the thinner dashed line delineates the point of no difference after treatment.
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damage might be a more prominent and irreversible process once
neurodegeneration persists, in agreement with the hypothesis of
an inflammatory endophenotype in AD patients.33 It should be
mentioned that 80% of patients in this study were at the early/
mild stage of AD, whereas only 20% at moderate/severe stage.
A subgroup analysis, according to CDR staging, in a significantly
larger sample would provide further insight to differences in
PBMC-secreted proinflammatory cytokines according to the
severity of AD.
Interestingly, while their overall cognitive performance was
not improved, AD patients receiving AChEI for 6 months exhib-
ited an improvement in depression symptoms, as indicated by
changes in the CSDD. Several studies have highlighted the
potential role of inflammation as the connecting link between
AD and depression.34 Patients with depression were also found
with elevated proinflammatory cytokines, and common treatment
targets have been proposed to protect from inflammation in AD
and depression.35 A previous clinical study showed that donepezil
treatment improved behavioral symptoms, including depres-
sion,36 while another study indicated that donepezil delayed more
effectively the progression of cognitive impairment in those patients
who were depressed at the beginning of donepezil treatment.37© 2018 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2018 Wolters Kluwer Health, Inc. UnauSeveral confounding factors could influence the present re-
sult (such as “placebo” effect of treated patients or improvement
of behavioral symptoms). Furthermore, there is no direct evidence
regarding how the cytokine findings relate to the therapeutic effect
(if any) of the AChEI. Moreover, the Ficoll–Hypaque method
does not selectively identify lymphocytes versus monocytes as
the source of cytokines and potential differences in these cells
could influence the overall outcome, along with systemic dis-
eases, infections, and inflammatory processes. However, all pa-
tients in this study where closely monitored and none displayed
such events. In addition, the comparison of PBMC-derived cyto-
kines in the prospective part of the study, where each patient is
tested before and after treatment, provides additional evidence
about the influence of AChEI treatment on overall. PBMC-derived
cytokines levels.
In summary, this study shows a striking difference in
proinflammatory cytokines, between controls versus drug-
naive and AChEI-treated AD patients. Moreover, AChEI
treatment, in this case donepezil, reduced proinflammatory cyto-
kines when examining patients before and after treatment. Fur-
ther studies are warranted to understand the role of such
modulation of cytokines by AChEIs and its possible role in
the progress of AD.www.psychopharmacology.com 5
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